Microbio appoints Jeff Bryant to drive global commercial strategy

Jeff Bryant
Jeff Bryant

Microbio Ltd, an Australian pathogen detection diagnostics company, is pleased to announce the appointment of Jeff Bryant as its Commercial Director. Mr Bryant will lead the company’s commercial team as it executes its global commercialisation strategy. With his extensive experience in market entry strategy, sales growth, and sales channel development, Mr Bryant brings valuable expertise to accelerate the company’s expansion and drive business success.

Mr Bryant is a seasoned professional dedicated to assisting life science companies achieve their growth objectives and exploring new markets and customers for their products and services. During his 25-year career, Mr Bryant has played pivotal sales and marketing roles at Agena Bioscience, Sequenom Inc, Becton Dickinson, Bio-Rad Laboratories, and Devyser AB Sweden. His contributions to commercial strategy development and implementation in the Asia Pacific region have resulted in sustainable sales growth, enduring customer relationships, highly effective distribution sales networks, and high-performance sales and customer support teams.

Mr Bryant’s ability to forge strategic partnerships and leverage influential networks has been instrumental in driving market adoption of new products globally.

“We are thrilled to welcome Jeff to our team at Microbio,” said Microbio CEO, Colin Keating.

 “Jeff’s knowledge and strategic insights will be invaluable as we commercialise Microbio’s flagship product, InfectID-BSI.”

As Microbio continues to revolutionize the molecular diagnostics landscape, the addition of Mr Bryant to the team signifies the company’s commitment to driving commercial success and advancing healthcare through innovative in vitro diagnostics.